Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Kumba Health is an online platform connecting doctors with patients. Kumba Health ...
Kumba Health is an online platform connecting d...
Evofem BiosciencesÂŽ exists to advance the lives of women. We believe this work ce...
Evofem BiosciencesÂŽ exists to advance the live...
slumberBUMP⢠was invented by Dr. Shad Morris, DMD from Premier Sleep Solutions. ...
slumberBUMP⢠was invented by Dr. Shad Morris,...
Precipio has built a platform designed to eradicate the problem of misdiagnosis by...
Precipio has built a platform designed to eradi...
GenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular di...
GenMark Diagnostics (NASDAQ: GNMK) is a leading...
Digirad delivers convenient, effective, and efficient healthcare solutions on an a...
Digirad delivers convenient, effective, and eff...
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inha...
Pulmatrix is a clinical stage biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.